Evolutionary characteristics of HIV type 1 variants resistant to protease inhibitors in the absence of drug-selective pressure

被引：17

作者：

Boeri, E

Gianotti, N

Canducci, F

Hasson, H

Giudici, B

Castagna, A

Lazzarin, A

Clementi, M

机构：

[1] Diagnost & Ric San Raffaele, Virol Lab, I-20127 Milan, Italy

[2] Ist Sci San Raffaele, IRCCS, Ctr San Luigi, Div Malattie Infett, Milan, Italy

[3] Univ Vita Salute San Raffaele, Milan, Italy

来源：

AIDS RESEARCH AND HUMAN RETROVIRUSES | 2003年 / 19卷 / 12期

关键词：

D O I：

10.1089/088922203771881257

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

To understand the evolutionary characteristics of HIV- 1 variants resistant to protease inhibitors ( PI), the replicating plasma virus was analyzed in three patients shifted to a PI- sparing regimen after virological failure. The dynamic features of carryover of mutations associated with PI resistance in the absence of selective pressure on the protease gene indicate that viral variants resistant to reverse transcriptase inhibitors and bearing mutations of the protease sequence can maintain efficient replication capacity in vivo.

引用

收藏

页码：1151 / 1153

页数：3

相关论文

共 14 条

[1] Resistance of human immunodeficiency virus type 1 to protease inhibitors: Selection of resistance mutations in the presence and absence of the drug [J].

Borman, AM ;

Paulous, S ;

Clavel, F .

JOURNAL OF GENERAL VIROLOGY, 1996, 77 :419-426

[2] Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors [J].

Croteau, G ;

Doyon, L ;

Thibeault, D ;

McKercher, G ;

Pilote, L ;

Lamarre, D .

JOURNAL OF VIROLOGY, 1997, 71 (02) :1089-1096

[3] Persistence of drug-resistant HIV-1 after a structured treatment interruption and its impact on treatment response [J].

Deeks, SG ;

Grant, RM ;

Wrin, T ;

Paxinos, EE ;

Liegler, T ;

Hoh, R ;

Martin, JN ;

Petropoulos, CJ .

AIDS, 2003, 17 (03) :361-370

[4] Re-occurrence of HIV-1 drug mutations after treatment re-initiation following interruption in patients with multiple treatment failure [J].

Delaugerre, C ;

Valantin, MA ;

Mouroux, M ;

Bonmarchand, M ;

Carcelain, G ;

Duvivier, C ;

Tubiana, R ;

Simon, A ;

Bricaire, F ;

Agut, H ;

Autran, B ;

Katlama, C ;

Calvez, V .

AIDS, 2001, 15 (16) :2189-2191

[5]

Devereux HL, 1999, AIDS, V13, pF123, DOI 10.1097/00002030-199912240-00001

[6] Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial [J].

Durant, J ;

Clevenbergh, P ;

Halfon, P ;

Delgiudice, P ;

Porsin, S ;

Simonet, P ;

Montagne, N ;

Boucher, CAB ;

Schapiro, JM ;

Dellamonica, P .

LANCET, 1999, 353 (9171) :2195-2199

[7] Evolution of human immunodeficiency virus type 1 populations after resumption of therapy following interruption and shift in resistance genotype [J].

Izopet, J ;

Souyris, C ;

Hance, A ;

Sandres-Sauné, K ;

Alvarez, M ;

Pasquier, C ;

Clavel, F ;

Puel, J ;

Massip, P .

JOURNAL OF INFECTIOUS DISEASES, 2002, 185 (10) :1506-1510

[8] Origin of human immunodeficiency virus type 1 quasispecies emerging after antiretroviral treatment interruption in patients with therapeutic failure [J].

Kijak, GH ;

Simon, V ;

Balfe, P ;

Vanderhoeven, J ;

Pampuro, SE ;

Zala, C ;

Ochoa, C ;

Cahn, P ;

Markowitz, M ;

Salomon, H .

JOURNAL OF VIROLOGY, 2002, 76 (14) :7000-7009

[9] Resistance-associated loss of viral fitness in human immunodeficiency virus type 1:: Phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients [J].

Mammano, F ;

Petit, C ;

Clavel, F .

JOURNAL OF VIROLOGY, 1998, 72 (09) :7632-7637

[10] Processivity and drug-dependence of HIV-1 protease: determinants of viral fitness in variants resistant to protease inhibitors [J].

Menzo, S ;

Monachetti, A ;

Balotta, C ;

Corvasce, S ;

Rusconi, S ;

Paolucci, S ;

Baldanti, F ;

Bagnarelli, P ;

Clementi, M .

AIDS, 2003, 17 (05) :663-671